TY - JOUR T1 - Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer JF - In Vivo JO - In Vivo SP - 1437 LP - 1441 DO - 10.21873/invivo.12395 VL - 35 IS - 3 AU - SONG PENG AU - WENHONG DONG AU - QIANGQIANG CHU AU - JIA MENG AU - HAITAO YANG AU - YINGYING DU AU - YU SUN AU - ROBERT M. HOFFMAN Y1 - 2021/05/01 UR - http://iv.iiarjournals.org/content/35/3/1437.abstract N2 - Background/Aim: Small-cell lung cancer (SCLC) is a recalcitrant disease with liver and other metastasis. The present study evaluated the efficacy of the traditional Chinese medicine Brucea javanica oil (BJO) combined with anlotinib, a multi-tyrosine kinase inhibitor with anti-angiogenic activity, on a nude-mouse model of SCLC liver metastasis. Materials and Methods: The mouse model was established by injecting NCI-H446 cells (1×106) in Matrigel (20 μl) into the upper liver lobe. All animals were randomized and assigned to three groups: Control (n=8); anlotinib alone (n=8; 3 mg/kg, qd×14+7-day interval with two cycles, oral); anlotinib plus BJO (n=8; 3 mg/kg anlotinib qd×14+7-day interval with two cycles, orally; BJO: 1 g/kg, qd×6 weeks, orally). Body weight was determined every week. Six weeks after initial treatment, tumors were collected for analysis of angiogenesis using immunohistochemistry. Results: The combination of anlotinib and BJO significantly inhibited growth of SCLC liver metastases and angiogenesis more than anlotinib monotherapy (p=0.043). In addition, BJO alleviated body-weight loss associated with anlotinib therapy, including general mouse condition. Conclusion: The results of the present study indicate that the combination of anlotinib with BJO is promisingly active against liver metastases of SCLC, and has clinical potential. ER -